Novacea, Inc. (Nasdaq: NOVC) 63% LOWER; ended its Phase 3 ASCENT-2 clinical trial of Asentar, the company's lead investigational cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE